Mumbai, India
Mumbai, India

Time filter

Source Type

Lorenzi L.,University of Brescia | Doring C.,Goethe University Frankfurt | Rausch T.,European Molecular Biology Laboratory EMBL | Benes V.,European Molecular Biology Laboratory EMBL | And 13 more authors.
Oncotarget | Year: 2017

Follicular dendritic cell (FDC)-sarcoma is a rare neoplasm with morphologic and phenotypic features of FDCs. It shows an extremely heterogeneous morphology, therefore, its diagnosis relys on the phenotype of tumor cells. Aim of the present study was the identification of new specific markers for FDC-sarcoma by whole transcriptome sequencing (WTS). Candidate markers were selected based on gene expression level and biological function. Immunohistochemistry was performed on reactive tonsils, on 22 cases of FDC-sarcomas and 214 control cases including 114 carcinomas, 87 soft tissue tumors, 5 melanomas, 5 thymomas and 3 interdigitating dendritic cell sarcomas. FDC secreted protein (FDCSP) and Serglycin (SRGN) proved to be specific markers of FDC and related tumor. They showed better specificity and sensitivity values than some well known markers used in FDC sarcoma diagnosis (specificity: 98.6%, and 100%, respectively; sensitivity: 72.73% and 68.18%, respectively). In our cohorts CXCL13, CD21, CD35, FDCSP and SRGN were the best markers for FDC-sarcoma diagnosis and could discriminate 21/22 FDC sarcomas from other mesenchymal tumors by linear discriminant analysis. In summary, by WTS we identified two novel FDC markers and by the analysis of a wide cohort of cases and controls we propose an efficient marker panel for the diagnosis of this rare and enigmatic tumor.


News Article | May 4, 2017
Site: news.europawire.eu

More than 3,000 medical laboratory industry professionals expected to attend the launch edition of MEDLAB Europe at the Barcelona Congress Centre in Spain Barcelona, Spain, 04-May-2017 — /EuropaWire/ — After many years of operating successful MEDLAB events around Africa, Asia and the Middle East, Informa Life Sciences Exhibitions, the worlds leading publishing and exhibitions company, has announced that the MEDLAB Series will be expanding its presence into Europe. Taking place at the Barcelona Congress Centre in Barcelona, Spain, from 13-15 September 2017, more than 3,000 industry professionals are expected to attend Europe’s leading event for laboratory management and diagnosis. With the European In-Vitro Diagnostics (IVD) market expected to reach USD 15.5 billion by 2024, a platform such as MEDLAB presents a huge opportunity for global laboratory industry leaders, including manufacturers, dealers and distributors, to make inroads into the European market. Housing international exhibitors and covering 2,000 sqm of exhibition space, MEDLAB Europe will give visitors from across the world an opportunity to access cutting-edge laboratory products, next-generation technology, innovative services and world-class educational content. According to Tom Coleman, Group Exhibition Director, MEDLAB Series: “The launch of MEDLAB Europe is in line with our global expansion strategy for our MEDLAB series of events. The increasing prevalence of chronic diseases, rising geriatric population coupled with the rising awareness towards early diagnosis, has positioned the European IVD and medical laboratory market as a critical market for manufacturers, services providers, and dealers and distributors from across the globe. MEDLAB Europe will generate substantial value for our customers and partners by driving further product innovation and deeper engagement in these specific markets.” Over the four-day event, MEDLAB Europe will also offer a multi-disciplinary congress tackling current challenges and developments key to the European market, and leveraging the true potential of laboratory testing to dramatically improve patient outcomes across the continent. The conference programme covers five main tracks including Point of Care Testing (POCT), Histopathology, Lab Management, Microbiology and Haematology. From new methods of effective lab management to the development of techniques in detecting diseases, the conferences will also review the expanding role of the laboratory medicine and discuss partnership between a clinician and a lab professional in providing delivery of care to every patient. “The scientific programme at MEDLAB has been carefully designed in collaboration with some of the brightest minds in the medical laboratory industry in order to have a real impact on improving the health and wellbeing of patients across the region,” said Coleman. For more information about the MEDLAB Europe Exhibition & Congress, please visit: www.medlabeurope.com.


News Article | May 4, 2017
Site: www.24-7pressrelease.com

BARCELONA, SPAIN, May 04, 2017-- After many years of operating successful MEDLAB events around Africa, Asia and the Middle East, Informa Life Sciences Exhibitions, the worlds leading publishing and exhibitions company, has announced that the MEDLAB Series will be expanding its presence into Europe. Taking place at the Barcelona Congress Centre in Barcelona, Spain, from 13-15 September 2017, more than 3,000 industry professionals are expected to attend Europe's leading event for laboratory management and diagnosis With the European In-Vitro Diagnostics (IVD) market expected to reach USD 15.5 billion by 2024 , a platform such as MEDLAB presents a huge opportunity for global laboratory industry leaders, including manufacturers, dealers and distributors, to make inroads into the European market. Housing international exhibitors and covering 2,000 sqm of exhibition space, MEDLAB Europe will give visitors from across the world an opportunity to access cutting-edge laboratory products, next-generation technology, innovative services and world-class educational content.According to Tom Coleman, Group Exhibition Director, MEDLAB Series: "The launch of MEDLAB Europe is in line with our global expansion strategy for our MEDLAB series of events. The increasing prevalence of chronic diseases, rising geriatric population coupled with the rising awareness towards early diagnosis, has positioned the European IVD and medical laboratory market as a critical market for manufacturers, services providers, and dealers and distributers from across the globe. MEDLAB Europe will generate substantial value for our customers and partners by driving further product innovation and deeper engagement in these specific markets."Over the four-day event, MEDLAB Europe will also offer a multi-disciplinary congress tackling current challenges and developments key to the European market, and leveraging the true potential of laboratory testing to dramatically improve patient outcomes across the continent.The conference programme covers five main tracks including Point of Care Testing (POCT), Histopathology Microbiology and Haematology . From new methods of effective lab management to the development of techniques in detecting diseases, the conferences will also review the expanding role of the laboratory medicine and discuss partnership between a clinician and a lab professional in providing delivery of care to every patient."The scientific programme at MEDLAB has been carefully designed in collaboration with some of the brightest minds in the medical laboratory industry in order to have a real impact on improving the health and wellbeing of patients across the region," said Coleman.For more information about the MEDLAB Europe Exhibition & Congress, please visit: www.medlabeurope.com Informa Life Sciences Exhibitions, in charge of the healthcare portfolio within Informa's Global Exhibitions division, organises 26 exhibitions yearly covering the Middle East, Africa, Asia, Europe and US market, connecting more than 150,000 healthcare professionals worldwide and offering a range of marketing solutions for companies involved with the healthcare sector. Over 100 congresses take place in parallel with the exhibitions.Informa Life Sciences Exhibitions publishes four international healthcare magazines, offers Dothealth, a healthcare portal showcasing over 40,000 healthcare companies and runs Healthy Change, an online recruitment portal.


Al-Qahtani K.H.,King Saud University | Al Asiri M.,Comprehensive Cancer Center | Tunio M.A.,Comprehensive Cancer Center | Aljohani N.J.,Endocrinology and Thyroid Oncology | And 3 more authors.
Journal of Otolaryngology - Head and Neck Surgery | Year: 2015

Background: Papillary Microcarcinoma (PMC) of thyroid is a rare type of differentiated thyroid cancer (DTC), which according to the World Health Organization measures 1.0 cm or less. The gold standard of treatment of PMC is still controversy. Our aim was to contribute in resolving the debate on the therapeutic choices of the surgical and adjuvant I-131 (RAI) treatment in PMC. Methods: From 2000 to 2012, 326 patients were found to have PMC and were retrospectively reviewed for clinicopathological characteristics, treatment outcomes and prognostic factors. Results: Mean age of cohort was 42.6 years (range: 18-76) and the mean tumor size was 0.61 cm ± 0.24; lymph node involvement was seen in 12.9 % of cases. Median follow up period was 8.05 years (1.62-11.4). Total 23 all site recurrences (7.13 %) were observed; more observed in patients without I-131 ablation (p <0.0001). Ten year DFS rates were 89.6 %. Cox regression Model analysis revealed size, histopathologic variants, multifocality, extrathyroidal extension, lymphovascular space invasion, nodal status, and adjuvant RAI ablation the important prognostic factors affecting DFS. Discussion: Despite excellent DFS rates, a small proportion of patients with PMC develop recurrences after treatment. Adjuvant RAI therapy improves DFS in PMC patients with aggressive histopathologic variants, multifocality, ETE, LVSI, tumor size (> 0.5 cm) and lymph node involvement. Failure of RAI ablation to decrease risk in N1a/b supports prophylactic central neck dissection during thyroidectomy, however more trials are warranted. Conclusion: Adjuvant I-131 ablation following thyroidectomy in PMC patients, particularly with poor prognostic factors improves DFS rates. © 2015 AL-Qahtani et al.


PubMed | Histopathology, King Abdulaziz University, King Saud University, Comprehensive Cancer Center and 2 more.
Type: | Journal: Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale | Year: 2015

Papillary Microcarcinoma (PMC) of thyroid is a rare type of differentiated thyroid cancer (DTC), which according to the World Health Organization measures 1.0cm or less. The gold standard of treatment of PMC is still controversy. Our aim was to contribute in resolving the debate on the therapeutic choices of the surgical and adjuvant I-131 (RAI) treatment in PMC.From 2000 to 2012, 326 patients were found to have PMC and were retrospectively reviewed for clinicopathological characteristics, treatment outcomes and prognostic factors.Mean age of cohort was 42.6years (range: 18-76) and the mean tumor size was 0.61cm0.24; lymph node involvement was seen in 12.9% of cases. Median follow up period was 8.05years (1.62-11.4). Total 23 all site recurrences (7.13%) were observed; more observed in patients without I-131 ablation (p <0.0001). Ten year DFS rates were 89.6%. Cox regression Model analysis revealed size, histopathologic variants, multifocality, extrathyroidal extension, lymphovascular space invasion, nodal status, and adjuvant RAI ablation the important prognostic factors affecting DFS.Despite excellent DFS rates, a small proportion of patients with PMC develop recurrences after treatment. Adjuvant RAI therapy improves DFS in PMC patients with aggressive histopathologic variants, multifocality, ETE, LVSI, tumor size (> 0.5 cm) and lymph node involvement. Failure of RAI ablation to decrease risk in N1a/b supports prophylactic central neck dissection during thyroidectomy, however more trials are warranted.Adjuvant I-131 ablation following thyroidectomy in PMC patients, particularly with poor prognostic factors improves DFS rates.


PubMed | S. Orsola Malpighi University Hospital, The Hospital for Sick Children, University of Barcelona, Italian National Cancer Institute and 8 more.
Type: | Journal: Molecular cancer research : MCR | Year: 2017

Follicular dendritic cell (FDC) sarcomas are rare mesenchymal tumors (MTs) with variable clinical, morphologic and phenotypic characteristics. Transcriptome analysis was performed on multiple FDC sarcomas and compared to other MTs, microdissected Castleman FDCs, and normal fibroblasts. Using unsupervised analysis, FDC sarcomas clustered with microdissected FDCs, distinct from other MTs and fibroblasts. The specific endowment of FDC-related gene expression programs in FDC sarcomas emerged by applying a gene signature of differentially expressed genes (n=1,289) between microdissected FDCs and fibroblasts. Supervised analysis comparing FDC sarcomas with microdissected FDCs and other MTs identified 370 and 2,927 differentially expressed transcripts, respectively, and based on pathway enrichment analysis ascribed to signal transduction, chromatin organization, and extracellular matrix organization programs. Since the transcriptome of FDC sarcomas retained similarity with FDCs, the immune landscape of FDC sarcoma was investigated by applying the CIBERSORT algorithm to FDC sarcomas and non-FDC MTs, and demonstrated that FDC sarcomas were enriched in T follicular helper (Tfh) and T regulatory (Treg) cell populations, as confirmed in situ by immunohistochemistry. The enrichment in specific T-cell subsets prompted investigating the mRNA expression of the inhibitory immune receptor PD-1 and its ligands PD-L1 and PD-L2, which were found to be significantly upregulated in FDC sarcomas as compared with other MTs, a finding also confirmed in situ. Here it is demonstrated for the first time the transcriptional relationship of FDC sarcomas with non-malignant FDCs and their distinction from other MTs.The current study provides evidence of a peculiar immune microenvironment associated with FDC sarcomas that may have clinical utility.


News Article | November 30, 2016
Site: www.newsmaker.com.au

Tissue is a group or layer of cells which perform a particular function and contain necessary biological information. Tissue samples are used for cancer diagnosis and analysis, where it captures the biological context of the disease. It conforms the presence of cancer by examining the tissue sample under microscope by a trained physician called a pathologist. Histopathology is a study of disease in a tissue which can be done by small biopsies, fine needle aspiration cytology and open biopsy or surgery. The three major types of tissue diagnosis, Hematoxylin and Eosin (H&E), Immunohistochemistry (IHC) and In situ hybridization. H&E stains work well with a variety of fixatives and displays a broad range of cytoplasmic, nuclear, and extracellular matrix features. Immunohistochemistry (IHC) is one of the most useful new diagnostic markers where proteins are stained using antibodies. And In situ hybridization identifies specific nucleotide sequences in the cells and tissues. Tissue Diagnosis technique is said to be one of the gold standards set in cancer diagnosis and is the crucial driver in the market. Tissue based diagnosis technique helps to determine the cause and effect of the disease in a patient. Due to unhealthy lifestyles of population the rate of cancer incidences is growing each year and so is driving the market for tissue based diagnosis. Cancer diagnosis at early stages and treatment will lead to better chances of survival and the market for diagnostics will show significant growth by forcing labs to increase efficiency in the diagnosis process to maximize health securities in patients. In developed countries there is enough health awareness as compared to the developing countries for which various factors are responsible as economic factors, low health literacy and increasing regulatory requirements hamper the market opportunities and growth. Tissue Diagnostic market is classified on the basis of product, technology, disease and end users. Based on the product type the global tissue diagnostic market is segmented into following: Based on the application the global tissue diagnostic market is segmented into following: Based on the disease the global tissue diagnostic market is segmented into following: Based on the end user the global tissue diagnostic market is segmented into following: Tissue Diagnostic market is a growing market due to increasing cancer awareness campaigns, advance research technology, improving healthcare infrastructure is leading to better market opportunities in tissue diagnostics. Personalized healthcare and companion diagnostics, IVD Development and Digital Pathology and Integrated Diagnostics are the major concerns of the tissue diagnostic market which are giving positive results and address health issues. Significant research is being carried out giving rise to the emerging technologies to meet the medical needs in the tissue diagnostic market. Tissue diagnostic market is also segmented into pre-analytical and advance stains on the basis of the examination time. Depending on geographic regions, global radiofrequency ablation system market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa. The global tissue market is segmented into seven regions amongst which North America is the largest tissue diagnostic market due to prevalence of cancer and health literacy supported by modern diagnostic techniques available. Europe is observed to be the second largest regional segment in the global tissue diagnostics market. The key market players in global tissue diagnostic market are F. Hoffmann-La Roche AG, Sigma-Aldrich Co. LLC, Abbott Laboratories, Agilent Technologies, BioGenex, Danaher Corporation, Cell Signaling Technology and Ventana Medical Systems.


News Article | November 24, 2015
Site: phys.org

Histopathology of Helicobacter pylori infection in a gastric foveolar pit demonstrated in endoscopic gastric biopsy. Credit: Wikipedia. Helicobacter pylori is a bacteria that lives in the gut of more than 50 per cent of the world's population, and is the most common bacterial infection worldwide. It is responsible for most peptic ulcers and is a significant risk factor for stomach cancer. Professors Peter Tyler and Gary Evans, and Dr Keith Clinch from Victoria's Ferrier Research Institute, have worked with Professor Vern Schramm from Albert Einstein College of Medicine in New York to develop 10 antibiotic candidates for treating the bacteria. "Developing a new antibiotic treatment for this bacteria has become important because of the development of resistance to drugs, the use of which tends to wipe out much of the gut's healthy bacteria as well," says Professor Tyler. "Our compounds target a pathway specific to this bacterium, by blocking the enzyme methylthioadenosine nucleosidase and interfering with production of an essential bacterial membrane component. This means we can selectively halt the growth of this bacterium, while not affecting other beneficial gut microbes." All ten of the antibiotic candidates identified by the research team have been proven to prevent the bacteria's growth at concentrations 16 to 2,000-fold lower than antibiotics commonly used to treat Helicobacter pylori infections. The research team has spent the past three years in the lab synthesising and testing the drug candidates, with their findings recently published by the Journal of the American Chemical Society. "This is a great achievement for Ferrier scientists, who have been heavily involved in the development of the compounds", says Director of the Ferrier Research Institute Professor Richard Furneaux.


PubMed | Histopathology, University of Barcelona, University of Bologna, Goethe University Frankfurt and 4 more.
Type: | Journal: European journal of cancer (Oxford, England : 1990) | Year: 2016

Follicular dendritic cell (FDC) sarcomas are rare mesenchymal tumours, which are fatal in 20% of the patients and usually occur in secondary lymphoid organs or extranodal localizations. Due to the rareness of these tumours, only few studies have been conducted on molecular level. In the present study, we performed microRNA (miRNA) profiling of 31 FDC sarcomas and identified two subgroups, one with high miRNA expression and the other group with low miRNA expression levels. The first group showed a strong similarity to fibroblasts and myopericytomas, whereas the second group was more closely related to FDCs from Castlemans disease. Both groups showed important differences compared with myeloid-derived dendritic cells, confirming mesenchymal origin of FDCs and their derived sarcomas. The two FDC sarcoma groups did not differ on morphological grounds, mitotic activity or BRAF mutation status. However, patients of group I presented a tendency to a shorter overall survival and more frequent podoplanin expression by immunohistochemistry. The importance of these newly recognized FDC sarcoma subgroups in terms of clinical behaviour and therapeutic implications should be assessed in a larger cohort in future studies.

Loading Histopathology collaborators
Loading Histopathology collaborators